Elia Seguí, MD

Meet Dr. Elia Seguí (@eliasegui.bsky.social), a new Advanced Fellow at the Breast Oncology Center at Dana-Farber. Dr. Seguí specializes in #BreastCancer and #ImmunoOncology. She finds immense fulfillment in combining patient care with academic research.

Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️

So how can we ever achieve #gender #equality?

We discuss various strategies in this #Cell Commentary

#WomeninSTEM

www.cell.com/cell/fulltex...
🧵 1/

Insightful translational study on chemo+IO in eTNBC dissecting chemo response vs IO response! Well done GBG! @cellpressnews.bsky.social #bcsm @oncoalert.bsky.social

missing u all!

For me it’s control over what I choose to expose myself to on a daily basis. I have thought a lot about quitting social media all together due to its negative impacts.

Looking for a space to share medical knowledge and research, be up to date. I don’t need an echo chamber but I do need sanity.

Definitely a must-read for anyone interested in the interplay between ER signaling and the tumor immune microenvironment. Incredible work by @ccortimd.bsky.social 👏👏
👉 Check it out here: doi.org/10.1016/j.ct...

Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!

Seeing this explosion of activity on BlueSky, I can’t help but feel excited about the possibilities. Let’s make this a space dedicated to vibrant scientific discussions, true collaboration, and inclusion for everyone 🧬

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!